Company Overview and News

0
Premier Explosives Limited - Investor Presentation

2018-05-23 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
PREMEXPLQ 526247

0
Premier Explosives Limited - Outcome of Board Meeting

2018-05-23 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
PREMEXPLQ 526247

0
Premier Explosives Limited - Financial Result Updates

2018-05-23 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
PREMEXPLQ 526247

0
Premier Explosives Limited - Dividend

2018-05-23 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
PREMEXPLQ 526247

0
Premier Explosives Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-05-22 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
PREMEXPLQ 526247

1
Nexter, PEL announce teaming

2018-04-16 janes
Nexter and India’s Premier Explosives Ltd (PEL) have agreed to jointly manufacture bi-modular charge systems (BMCSs) in the hope of fulfilling an Indian Ministry of Defence requirement.
PREMEXPLQ 526247

0
Premier Explosives gains 6% on tie-up with French firm for manufacturing defence products

2018-04-13 moneycontrol
Premier Explosives share price gained 6.5 percent intraday Friday on pact with French company for defence products.
PREMEXPLQ 526247

50
Market Live: Sensex gains strength again; IT stocks strong ahead of Infosys earnings

2018-04-13 moneycontrol
1:47 pm Market Update: The market gained strength against in afternoon as technology stocks and Reliance Industries continued to support, but the selling pressure select banks capped upside.
500325 JIPKY HCTHY JBFIND 526247 532281 RLNIY ASHOKLEY SBAZ AXB 590134 MADRASFERT AKLD AXBA FORTIS HCLTECH 500180 KOTAKBANK AKLS WFCNP RELIANCE WFC.PRL WFC.PRJ 514034 532215 WFC.PRT WFC.PRR WFC.PRQ WFC.PRP WFC.PRO AXISBANK WFC.PRN RIGD HDFCBANK 500477 WFC.PRY WFC.PRX WFC.PRW WFC.PRV WFC WFC.WS PREMEXPLQ KMBKY JPASSOCIAT 532843 AXBKY 532532 HDB 500247

0
Premier Explosives Limited - Updates

2018-04-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
PREMEXPLQ 526247

Related Articles

HIMX: Himax Technologies Analysis and Research Report

17h - Asif

History and Development Himax Taiwan, its predecessor, was incorporated on June 12, 2001 as a limited liability company under the laws of the ROC. On April 26, 2005, the company established Himax Technologies Limited, an exempted company with limited liability under the Cayman Islands Companies Law, as a holding company to hold the shares of Himax Taiwan in connection with its reorganization and share exchange. On October 14, 2005, Himax Taiwan became its wholly owned subsidiary through a share exchange consummated pursuant to the ROC Business Mergers and Acquisitions Law through which the company acquired all of the issued and outstanding shares of Himax Taiwan, and the company issued ordinary shares to the shareholders of Himax Taiwan. Shareholders of Himax Taiwan received one of its ordinary shares in exchange for one Himax Taiwan common share. The share exchange was unanimously approved by shareholders of Himax Taiwan on June 10, 2005 with no dissenting shareholders and by ...

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...